ACTRN12617001394336已完成1 期
A comparative study of the parasitological response to single dose artesunate therapy among healthy subjects experimentally infected with either the artemisinin-resistant Plasmodium falciparum isolate K13 or the artemisinin-sensitive isolate 3D7
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Adult (male and non-pregnant, non-lactating female) subjects between 18 and 55 years of age inclusive, who do not live alone (from inoculation day until the end of the antimalarial treatment) and will be contactable and available for the duration of the trial and up to 2 weeks following the End of Study visit (approximately 6 weeks).
- •2.Body weight minimum 50 kg, body mass index between 18 and 32 kg/m2, inclusive.
- •3.Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- •4.Normal standard 12-lead ECG after 5 minutes resting in supine position.
- •5.Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects enrolled in this study.
- •6.Female participants of childbearing potential should be surgically sterile or using an insertable, injectable, transdermal or combination oral contraceptive approved by the Therapeutic Goods Administration combined with a barrier contraceptive for the duration of the study, and have negative results on a serum pregnancy test done before malaria parasite inoculation.
排除标准
- •1.Any history of malaria or participation in a previous malaria challenge study.
- •2.Must not have travelled to or lived (>2 weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region during the course of the study.
- •3.Has evidence of increased cardiovascular disease risk.
- •4.History of splenectomy.
- •5.Presence of acute infectious disease or fever (e.g., sublingual temperature greater than or equal to 38.5 degrees C) within the 5 days prior to inoculation with malaria parasites.
- •6.Evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise subject safety.
- •7.Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion, e.g. gastrectomy, diarrhoea.
- •8.Participation in any investigational product study within the 12 weeks preceding the study.
- •9.Blood donation of any volume within 1 month before inclusion, or participation in any research study involving blood sampling (more than 450 mL/unit of blood), or blood donation to a blood bank during the 8 weeks prior to the treatment drug dose in the study.
- •10.Subject who has ever received a blood transfusion.
- •11.Any vaccination within the last 28 days.
- •12.Any recent (less than 6 weeks) or current systemic therapy with an antibiotic or drug with potential antimalarial activity (i.e. chloroquine, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.)
- •13.Cardiac/QT risk
- •14.Known hypersensitivity to artesunate or any of its excipients, artemether or other artemisinin derivatives, piperaquine, atovaquone/proguanil hydrochloride, primaquine, or 4-aminoquinolines.
- •15.Unwillingness to abstain from consumption of grapefruit or Seville oranges from inoculation day until end of antimalarial treatment.
研究者
相似试验
撤回
不适用
Efficacy and safety of (a) A-Lfor Plasmodium falciparum and (b) P-A for Plasmodium falciparum and Plasmodium vivax malaria in Ta-mu Township, Sagaing Regiomalaria related feverheadacheachemailaiseloss of appetitePublic Health - Other public healthInfection - Other infectious diseasesACTRN12618001476224WHO country office50
已完成
3 期
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum MalariaMalariaNCT00316329Sanofi1,032
已完成
4 期
Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLeranceMalariaNCT00445796Sanofi300
尚未招募
4 期
Assessment of combined antiparasitic drugs praziquantel and albendazole versus albendazole alone in the treatment of active parenchymal neurocysticercosis in Tanzania and Zambia.NeurocysticercosisPACTR202402822223203REvolution Worldwide S.r.l. Impresa Sociale300
尚未招募
2 期
Effect of sweet basil varnish on Dental cariesCTRI/2024/05/067132Dr Siva Shankkari T